3-(2,2,2-trimethylhydrazine)propionate has been researched along with Cardiovascular Stroke in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cirule, H; Dambrova, M; Grinberga, S; Kuka, J; Liepinsh, E; Makrecka, M; Pugovics, O; Sevostjanovs, E; Skapare, E; Vavers, E | 1 |
| Shilina, NN; Statsenko, ME; Turkina, SV | 2 |
| Nechaeva, GI; Potashov, DA; Zheltikova, EN | 1 |
| Nechaeva, GI; Zheltikova, EN | 1 |
| Cirule, H; Dambrova, M; Kalvinsh, I; Kuka, J; Liepinsh, E; Veveris, M; Vilskersts, R | 1 |
| Cirule, H; Dambrova, M; Kalvinsh, I; Kuka, J; Liepinsh, E; Makrecka, M; Pugovics, O; Vilskersts, R | 1 |
| Mamchur, SE; Sankevitch, TV; Stepatcheva, TA; Teplyakov, AT | 1 |
| Glonti, TG; Gorgoshidze, ML; Svanidze, TD; Tsintsadze, IN | 1 |
| Kalvinsh, I; Kloner, RA; Sesti, C; Simkhovich, BZ | 1 |
| Dambrova, M; Kalvinsh, I; Kirjanova, O; Liepinsh, E; Loca, D; Pugovichs, O; Vilskersts, R | 1 |
| Belenkova, SV; Shilina, NN; Sporova, OE; Statsenko, ME | 1 |
| Asaka, N; Hayashi, Y; Kirimoto, T; Matsuura, N; Miyake, H; Nakano, M; Tajima, K | 1 |
| Hayashi, Y; Hoshiai, K; Hoshiai, M; Ishida, H; Kanno, T; Kirimoto, T; Matsuura, N; Miyake, H; Nakano, M; Nakazawa, H; Tajima, K | 1 |
| Aoyagi, T; Eto, Y; Hayashi, Y; Kirimoto, T; Matsumoto, A; Momomura, S; Omata, M; Sugiura, S; Yokoyama, I; Yonekura, K | 1 |
1 review(s) available for 3-(2,2,2-trimethylhydrazine)propionate and Cardiovascular Stroke
| Article | Year |
|---|---|
[[Meldonium in treatment of patients with myocardial infarction].
Topics: Cardiotonic Agents; Cardiovascular Agents; Humans; Metabolism; Methylhydrazines; Myocardial Infarction; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
6 trial(s) available for 3-(2,2,2-trimethylhydrazine)propionate and Cardiovascular Stroke
| Article | Year |
|---|---|
[Role of pFox inhibitors in the treatment of patients with acute myocardial ischemia].
Topics: Administration, Oral; Aged; Cardiovascular Agents; Dose-Response Relationship, Drug; Electrocardiography; Exercise Tolerance; Female; Forkhead Transcription Factors; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Infarction; Prospective Studies; Treatment Outcome | 2014 |
[Use of meldonium in the combination treatment of patients with heart failure in the early postinfarction period].
Topics: Aged; Cardiovascular Agents; Diastole; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Humans; Injections, Intravenous; Male; Methylhydrazines; Middle Aged; Myocardial Infarction; Systole; Treatment Outcome | 2014 |
[Effects of Meldonium in Early Postmyocardial Infarction Period].
Topics: Adult; Aged; Cardiovascular Agents; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Infarction; Prognosis; Prospective Studies; Time Factors; Treatment Outcome | 2015 |
[The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Atenolol; Cardiovascular Agents; Drug Therapy, Combination; Humans; Male; Methylhydrazines; Middle Aged; Mitochondrial Trifunctional Protein; Multienzyme Complexes; Myocardial Infarction; Ventricular Dysfunction, Left | 2003 |
[Effects of metabolic triad (25% polarizing solution, mildronat, preductal MR) in acute myocardial infarction].
Topics: Adult; Aged; Cardiovascular Agents; Drug Therapy, Combination; Female; Glucose; Humans; Insulin; Male; Methylhydrazines; Middle Aged; Myocardial Infarction; Potassium; Trimetazidine; Vasodilator Agents | 2006 |
[The use of mildronate in combined therapy of postinfarction chronic heart failure in patients with type 2 diabetes mellitus].
Topics: Cardiovascular Agents; Chronic Disease; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Infarction; Prospective Studies | 2007 |
8 other study(ies) available for 3-(2,2,2-trimethylhydrazine)propionate and Cardiovascular Stroke
| Article | Year |
|---|---|
Activated peroxisomal fatty acid metabolism improves cardiac recovery in ischemia-reperfusion.
Topics: Animals; Carnitine; Carnitine O-Palmitoyltransferase; Fatty Acids; Gene Expression Regulation; Male; Methylhydrazines; Mitochondria; Myocardial Infarction; Myocardial Reperfusion Injury; Oxidation-Reduction; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Peroxisomes; PPAR alpha; Rats; Rats, Wistar; Transcription Factors | 2013 |
Myocardial infarct size-limiting and anti-arrhythmic effects of mildronate orotate in the rat heart.
Topics: Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Male; Methylhydrazines; Myocardial Infarction; Necrosis; Orotic Acid; Rats; Rats, Wistar; Reperfusion Injury | 2009 |
The cardioprotective effect of mildronate is diminished after co-treatment with L-carnitine.
Topics: Animals; Betaine; Cardiovascular Agents; Carnitine; Carnitine O-Palmitoyltransferase; Chromatography, Liquid; Drug Interactions; Fatty Acids; Male; Methylhydrazines; Mitochondria, Heart; Mitochondrial Membranes; Myocardial Infarction; Myocardial Reperfusion Injury; Rats; Rats, Wistar; Tandem Mass Spectrometry; Vitamin B Complex | 2012 |
Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics.
Topics: Angina Pectoris; Animals; Blood Pressure; Body Weight; Cardiovascular Agents; Fatty Acids; Female; Heart Rate; Methylhydrazines; Myocardial Infarction; Oxidation-Reduction; Rats; Rats, Sprague-Dawley | 2006 |
Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction.
Topics: Animals; Betaine; Cardiovascular Agents; Carnitine; Chromatography, High Pressure Liquid; Coronary Circulation; gamma-Butyrobetaine Dioxygenase; In Vitro Techniques; Injections, Intraperitoneal; Male; Methylhydrazines; Myocardial Infarction; Myocardium; Rats; Rats, Wistar | 2006 |
Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Body Weight; Cardiovascular Agents; gamma-Butyrobetaine Dioxygenase; Heart Failure; Heart Ventricles; Hemodynamics; Lactic Acid; Male; Methylhydrazines; Mixed Function Oxygenases; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Survival Rate | 2000 |
MET-88, a gamma-butyrobetaine hydroxylase inhibitor, improves cardiac SR Ca2+ uptake activity in rats with congestive heart failure following myocardial infarction.
Topics: Adenine Nucleotides; Animals; Calcium; Captopril; Cardiovascular Agents; Energy Metabolism; Enzyme Inhibitors; gamma-Butyrobetaine Dioxygenase; Heart; Heart Failure; In Vitro Techniques; Male; Methylhydrazines; Mixed Function Oxygenases; Myocardial Infarction; Myocardium; Rats; Rats, Sprague-Dawley; Sarcoplasmic Reticulum | 2000 |
Inhibition of carnitine synthesis modulates protein contents of the cardiac sarcoplasmic reticulum Ca2+-ATPase and hexokinase type I in rat hearts with myocardial infarction.
Topics: Animals; Calcium-Transporting ATPases; Cardiovascular Agents; Carnitine; Hexokinase; Isoenzymes; Male; Methylhydrazines; Myocardial Infarction; Myocardium; Rats; Rats, Sprague-Dawley; Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2000 |